Changes in the pricing strategy for Novo Nordisk's new drug hope Ozempic have caused larger regulatory problems in the EU than expected, and have impacted the launch in European countries. But the pharmaceutical company has just received an important approval, which will enable a launch in the second half of the year.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.